<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03259893</url>
  </required_header>
  <id_info>
    <org_study_id>H-36040</org_study_id>
    <secondary_id>H-36040</secondary_id>
    <nct_id>NCT03259893</nct_id>
  </id_info>
  <brief_title>Secondary Prevention of Atrial Fibrilation</brief_title>
  <official_title>Boston Medical Center Secondary Prevention of Atrial Fibrillation Randomized Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BU Clinical Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is the most common arrhythmia affecting over 3 million Americans and&#xD;
      about 33.5 million individuals globally. The lifetime risk of developing AF is 1 in 4 for&#xD;
      adults over age 40 years. AF is associated with a major medical and socioeconomic burden&#xD;
      including high cost, increased risk of stroke, heart failure, dementia, myocardial&#xD;
      infarction, and death. Numerous studies have demonstrated that modifiable risk factors&#xD;
      including hypertension, obesity, sleep apnea, diabetes, and sedentary lifestyle predict the&#xD;
      development of AF.&#xD;
&#xD;
      Recent studies have reported that secondary prevention interventions through aggressive risk&#xD;
      factor modification can reduce the burden of AF. Structured, physician and nursing-led&#xD;
      interdisciplinary AF programs have been shown to improve patient adherence to guideline&#xD;
      recommendations and improve long term prognosis. Previous data, however, are derived mainly&#xD;
      from white European and Australian cohorts and it is unclear whether such interventions can&#xD;
      be effectively implemented in a racially diverse, safety net hospital in the U.S.&#xD;
&#xD;
      This study is a randomized hybrid implementation-effectiveness study designed to investigate&#xD;
      feasibility and effectiveness of an evidence-based innovative AF program, focusing on risk&#xD;
      factor modification and AF education in a racially mixed population receiving care in a&#xD;
      safety net hospital.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is designed as a Hybrid Type 3 effectiveness-implementation study. This&#xD;
      study design will enable the investigators to primarily focus on core implementation outcomes&#xD;
      while also assessing the effectiveness of the intervention on clinical outcomes. Since this&#xD;
      is a Type 3 Hybrid trial, there are both effectiveness and implementation evaluation&#xD;
      components, but the primary focus is on the implementation outcomes of feasibility,&#xD;
      acceptability, adoption, and appropriateness. The specific aims, data collection, and&#xD;
      analytic plans are grounded in the Proctor Conceptual Model of Implementation Research that&#xD;
      posits improvements in outcomes are dependent not only on the evidence-based interventions&#xD;
      that are implemented but on the implementation strategies used to implement those&#xD;
      interventions. The model distinguishes between the intervention strategy (evidence-based&#xD;
      practice), different types of implementation strategies (system environment, organizational,&#xD;
      group/learning, supervision, individual providers/consumers), and three levels of outcomes&#xD;
      (implementation, service, and client). The appropriate outcome measures in each category&#xD;
      (implementation, service, client) depend upon the specific evidence-based practice and local&#xD;
      context.&#xD;
&#xD;
      AF patients with a BMI of ≥ 27 kg/m2, who are referred to outpatient cardiology clinic,&#xD;
      inpatient cardiology service, or cardiology consult service at Boston Medical Center (BMC)&#xD;
      will be screened until 50 participants are enrolled. Eligible participants will undergo 1:1&#xD;
      randomization to standard of care (SoC -group 1) or to the interdisciplinary AF program&#xD;
      (intervention- group 2). Randomization will be performed using a computer randomizer&#xD;
      algorithm with 5 blocks of 6 and 5 blocks of 4 in random order for a total of 50&#xD;
      participants. The rational for the randomization design is primarily for the purpose of&#xD;
      feasibility and to establish effect sizes and guide the design of the future trial.&#xD;
&#xD;
      All patients will be enrolled for a total duration of six months. Outcomes will be measured&#xD;
      via 30-minute individual interviews at the end of 6-months. The implementation and service&#xD;
      outcomes will be examined including acceptability, appropriateness, adoption, feasibility,&#xD;
      and patient centeredness, as well as the client outcomes of satisfaction, function and&#xD;
      symptomatology. Data will be collected using both quantitative and qualitative data methods&#xD;
      to determine which aspects of the program achieved good patient adherence and acceptability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Initially suspended due to COVID-19 policies, it will not be possible to restart.&#xD;
  </why_stopped>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Actual">May 11, 2020</completion_date>
  <primary_completion_date type="Actual">May 11, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of the AF program</measure>
    <time_frame>6 months</time_frame>
    <description>Quantitative measure of willingness to enroll and attend nutrition clinic, cardiac rehabilitation clinic, and frequency of use of Alivecor device, smart Scale, Fitbit device will be aggregated to generate a single feasibility score to determine overall feasibility of the AF program.&#xD;
The feasibility score will be generated by the following formula:&#xD;
= 100 * average of { (actual nutrition clinic attendance/ expected nutrition clinic attendance) + (actual cardiac rehab clinic attendance/ expected cardiac rehab clinic attendance) + (actual use of smart phone enabled devices/expected use of smart phone enabled devices)}&#xD;
A feasibility score closer to 100% indicates good feasibility.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptability of the AF program</measure>
    <time_frame>6 months</time_frame>
    <description>Data from qualitative interviews will be coded using a process analytic framework and inductive logic to create a set of conceptual categories using the Constant Comparative Method and used to assess patient-centeredness and satisfaction which will reflect acceptability of the AF program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Most acceptable individual component of the AF program</measure>
    <time_frame>6 months</time_frame>
    <description>Data from qualitative interviews will be coded using a process analytic framework and inductive logic to create a set of conceptual categories using the Constant Comparative Method and used to compare the acceptability of individual component of AF programs including nutrition clinic, cardiac rehabilitation clinic, smoking cessation clinic, smart phone enable health devices.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Most adopted individual component of the AF program</measure>
    <time_frame>6 months</time_frame>
    <description>Quantitative measure of (actual clinic attendance or use of smart phone enable devices) / (expected clinic attendance or use of smart phone enable devices) will be compared for the various components of the AF program including nutrition clinic, cardiac rehabilitation clinic, smoking cessation clinic, Alivecor device, Fitbit device, smart blood pressure monitor, and smart scale. The individual component with the highest % attendance or use will be considered to be the most adopted individual component of the AF program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Burden of atrial fibrillation</measure>
    <time_frame>Twice weekly for 6 months</time_frame>
    <description>Quantitative measure of telemetry data from Alivecor devices, participants will be instructed to transmit telemetry data twice weekly and during symptomatic AF episodes. Telemetry data showing AF will be used to determine number of AF episodes in each participant over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation symptoms</measure>
    <time_frame>6 months</time_frame>
    <description>quantitative measure of telemetry data from Alivecor devices and qualitative measures using The Atrial Fibrillation Effect on QualiTy of Life (AFEQT) questionnaire is a 20 question, 7 point Likert scale (1-7) instrument that takes about 5 minutes to complete and evaluates Health Related Quality of Life across 3 domains- symptoms (4 questions), daily activities (8 questions), and treatment concerns (6 questions). The range of scores are 20-140, lower scores are favorable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation literacy</measure>
    <time_frame>6 months</time_frame>
    <description>AF Knowledge Questionnaire is a 34 question instrument that takes about 10 minutes to complete. It is a modified version of the Jessa Atrial fibrillation Knowledge Questionnaire (JAKQ) and contains questions about AF in general and about oral anticoagulation therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Fibrillation Effect on Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <description>The Atrial Fibrillation Effect on QualiTy of Life (AFEQT) questionnaire is a 20 question, 7 point Likert scale (1-7) instrument that takes about 5 minutes to complete and evaluates Health Related Quality of Life across 3 domains- symptoms (4 questions), daily activities (8 questions), and treatment concerns (6 questions). The range of scores are 20-140, lower scores are favorable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for atrial fibrillation</measure>
    <time_frame>6 months</time_frame>
    <description>quantitative measure of number of hospitalization for atrial fibrillation or outcome attributed to atrial fibrillation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Weight loss</measure>
    <time_frame>6 months</time_frame>
    <description>Quantitative measure of total weight loss over the duration of the study</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Risk Factors</condition>
  <condition>Risk Reduction Behavior</condition>
  <arm_group>
    <arm_group_label>Standard of care group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to the standard of care group will receive guideline-directed medical therapy according to clinical standard practice at Boston Medical Center. Each participant will receive an AliveCor mobile ECG cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group will receive the AF program which include a bundle of sub-interventions that target specific AF risk factors including hypertension, obesity, physical inactivity, sleep hygiene, and smoking. Each participant will receive an AliveCor mobile ECG cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AliveCor mobile ECG cardiac monitor</intervention_name>
    <description>AliveCor mobile ECG cardiac monitor is capable of providing real-time heart telemetry using a smart phone. Participants will be instructed to transmit rhythm data twice weekly and during symptomatic AF.</description>
    <arm_group_label>Intervention group 2</arm_group_label>
    <arm_group_label>Standard of care group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>AF Program</intervention_name>
    <description>The AF program includes a bundle of sub-interventions that target specific AF risk factors including hypertension, obesity, physical inactivity, sleep hygiene, and smoking. Participants randomized to the intervention group 2 will undergo counseling by the nurse and guided through the structured, goal-directed AF program. Each participant will receive an AliveCor cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.</description>
    <arm_group_label>Intervention group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Guideline-directed medical therapy according to clinical standard practice at Boston Medical Center.</description>
    <arm_group_label>Standard of care group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Diagnosis of paroxysmal AF (based on 12-lead electrocardiogram or event monitor&#xD;
             showing AF).&#xD;
&#xD;
          -  Body mass index of greater than 27 kg/m2&#xD;
&#xD;
          -  Eligibility to participate in cardiac rehabilitation with negative exercise stress&#xD;
             test within 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Permanent AF.&#xD;
&#xD;
          -  Undergone catheter ablation of AF in past 6 months.&#xD;
&#xD;
          -  Class I or Class III anti-arrhythmic drugs at the time of enrollment&#xD;
&#xD;
          -  Unable to participate in cardiac rehabilitation.&#xD;
&#xD;
          -  Prognosis of less than 1-year.&#xD;
&#xD;
          -  Do not own a smart phone.&#xD;
&#xD;
          -  Unable to operate (transmit data) their smart phone.&#xD;
&#xD;
          -  Are not fluent in English or Spanish.&#xD;
&#xD;
          -  Unable to read in English or Spanish.&#xD;
&#xD;
          -  Not able to provide informed consent.&#xD;
&#xD;
          -  Women who are pregnant.&#xD;
&#xD;
          -  Prisoners.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Helm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 4, 2017</study_first_submitted>
  <study_first_submitted_qc>August 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2017</study_first_posted>
  <last_update_submitted>January 23, 2021</last_update_submitted>
  <last_update_submitted_qc>January 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Proctor Conceptual Model of Implementation Research</keyword>
  <keyword>Prevention</keyword>
  <keyword>Safety net hospital</keyword>
  <keyword>Diverse inner city patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03259893
org study id: H-36040
secondary id: H-36040
nct id: NCT03259893
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
is us export: Yes
Atrial fibrillation (AF) is the most common arrhythmia affecting over 3 million Americans and
      about 33.5 million individuals globally. The lifetime risk of developing AF is 1 in 4 for
      adults over age 40 years. AF is associated with a major medical and socioeconomic burden
      including high cost, increased risk of stroke, heart failure, dementia, myocardial
      infarction, and death. Numerous studies have demonstrated that modifiable risk factors
      including hypertension, obesity, sleep apnea, diabetes, and sedentary lifestyle predict the
      development of AF.

      Recent studies have reported that secondary prevention interventions through aggressive risk
      factor modification can reduce the burden of AF. Structured, physician and nursing-led
      interdisciplinary AF programs have been shown to improve patient adherence to guideline
      recommendations and improve long term prognosis. Previous data, however, are derived mainly
      from white European and Australian cohorts and it is unclear whether such interventions can
      be effectively implemented in a racially diverse, safety net hospital in the U.S.

      This study is a randomized hybrid implementation-effectiveness study designed to investigate
      feasibility and effectiveness of an evidence-based innovative AF program, focusing on risk
      factor modification and AF education in a racially mixed population receiving care in a
      safety net hospital.
The proposed study is designed as a Hybrid Type 3 effectiveness-implementation study. This
      study design will enable the investigators to primarily focus on core implementation outcomes
      while also assessing the effectiveness of the intervention on clinical outcomes. Since this
      is a Type 3 Hybrid trial, there are both effectiveness and implementation evaluation
      components, but the primary focus is on the implementation outcomes of feasibility,
      acceptability, adoption, and appropriateness. The specific aims, data collection, and
      analytic plans are grounded in the Proctor Conceptual Model of Implementation Research that
      posits improvements in outcomes are dependent not only on the evidence-based interventions
      that are implemented but on the implementation strategies used to implement those
      interventions. The model distinguishes between the intervention strategy (evidence-based
      practice), different types of implementation strategies (system environment, organizational,
      group/learning, supervision, individual providers/consumers), and three levels of outcomes
      (implementation, service, and client). The appropriate outcome measures in each category
      (implementation, service, client) depend upon the specific evidence-based practice and local
      context.

      AF patients with a BMI of ≥ 27 kg/m2, who are referred to outpatient cardiology clinic,
      inpatient cardiology service, or cardiology consult service at Boston Medical Center (BMC)
      will be screened until 50 participants are enrolled. Eligible participants will undergo 1:1
      randomization to standard of care (SoC -group 1) or to the interdisciplinary AF program
      (intervention- group 2). Randomization will be performed using a computer randomizer
      algorithm with 5 blocks of 6 and 5 blocks of 4 in random order for a total of 50
      participants. The rational for the randomization design is primarily for the purpose of
      feasibility and to establish effect sizes and guide the design of the future trial.

      All patients will be enrolled for a total duration of six months. Outcomes will be measured
      via 30-minute individual interviews at the end of 6-months. The implementation and service
      outcomes will be examined including acceptability, appropriateness, adoption, feasibility,
      and patient centeredness, as well as the client outcomes of satisfaction, function and
      symptomatology. Data will be collected using both quantitative and qualitative data methods
      to determine which aspects of the program achieved good patient adherence and acceptability.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Prevention
masking: None (Open Label)
measure: Feasibility of the AF program
time frame: 6 months
description: Quantitative measure of willingness to enroll and attend nutrition clinic, cardiac rehabilitation clinic, and frequency of use of Alivecor device, smart Scale, Fitbit device will be aggregated to generate a single feasibility score to determine overall feasibility of the AF program.
The feasibility score will be generated by the following formula:
= 100 * average of { (actual nutrition clinic attendance/ expected nutrition clinic attendance) + (actual cardiac rehab clinic attendance/ expected cardiac rehab clinic attendance) + (actual use of smart phone enabled devices/expected use of smart phone enabled devices)}
A feasibility score closer to 100% indicates good feasibility.
measure: Acceptability of the AF program
time frame: 6 months
description: Data from qualitative interviews will be coded using a process analytic framework and inductive logic to create a set of conceptual categories using the Constant Comparative Method and used to assess patient-centeredness and satisfaction which will reflect acceptability of the AF program.
measure: Most acceptable individual component of the AF program
time frame: 6 months
description: Data from qualitative interviews will be coded using a process analytic framework and inductive logic to create a set of conceptual categories using the Constant Comparative Method and used to compare the acceptability of individual component of AF programs including nutrition clinic, cardiac rehabilitation clinic, smoking cessation clinic, smart phone enable health devices.
measure: Most adopted individual component of the AF program
time frame: 6 months
description: Quantitative measure of (actual clinic attendance or use of smart phone enable devices) / (expected clinic attendance or use of smart phone enable devices) will be compared for the various components of the AF program including nutrition clinic, cardiac rehabilitation clinic, smoking cessation clinic, Alivecor device, Fitbit device, smart blood pressure monitor, and smart scale. The individual component with the highest % attendance or use will be considered to be the most adopted individual component of the AF program.
measure: Burden of atrial fibrillation
time frame: Twice weekly for 6 months
description: Quantitative measure of telemetry data from Alivecor devices, participants will be instructed to transmit telemetry data twice weekly and during symptomatic AF episodes. Telemetry data showing AF will be used to determine number of AF episodes in each participant over time.
measure: Atrial fibrillation symptoms
time frame: 6 months
description: quantitative measure of telemetry data from Alivecor devices and qualitative measures using The Atrial Fibrillation Effect on QualiTy of Life (AFEQT) questionnaire is a 20 question, 7 point Likert scale (1-7) instrument that takes about 5 minutes to complete and evaluates Health Related Quality of Life across 3 domains- symptoms (4 questions), daily activities (8 questions), and treatment concerns (6 questions). The range of scores are 20-140, lower scores are favorable.
measure: Atrial fibrillation literacy
time frame: 6 months
description: AF Knowledge Questionnaire is a 34 question instrument that takes about 10 minutes to complete. It is a modified version of the Jessa Atrial fibrillation Knowledge Questionnaire (JAKQ) and contains questions about AF in general and about oral anticoagulation therapy.
measure: Atrial Fibrillation Effect on Quality of Life
time frame: 6 months
description: The Atrial Fibrillation Effect on QualiTy of Life (AFEQT) questionnaire is a 20 question, 7 point Likert scale (1-7) instrument that takes about 5 minutes to complete and evaluates Health Related Quality of Life across 3 domains- symptoms (4 questions), daily activities (8 questions), and treatment concerns (6 questions). The range of scores are 20-140, lower scores are favorable.
measure: Hospitalization for atrial fibrillation
time frame: 6 months
description: quantitative measure of number of hospitalization for atrial fibrillation or outcome attributed to atrial fibrillation
measure: Weight loss
time frame: 6 months
description: Quantitative measure of total weight loss over the duration of the study
arm group label: Standard of care group 1
arm group type: Active Comparator
description: Participants randomized to the standard of care group will receive guideline-directed medical therapy according to clinical standard practice at Boston Medical Center. Each participant will receive an AliveCor mobile ECG cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
arm group label: Intervention group 2
arm group type: Experimental
description: The intervention group will receive the AF program which include a bundle of sub-interventions that target specific AF risk factors including hypertension, obesity, physical inactivity, sleep hygiene, and smoking. Each participant will receive an AliveCor mobile ECG cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
intervention type: Other
intervention name: AliveCor mobile ECG cardiac monitor
description: AliveCor mobile ECG cardiac monitor is capable of providing real-time heart telemetry using a smart phone. Participants will be instructed to transmit rhythm data twice weekly and during symptomatic AF.
arm group label: Intervention group 2
arm group label: Standard of care group 1
intervention type: Behavioral
intervention name: AF Program
description: The AF program includes a bundle of sub-interventions that target specific AF risk factors including hypertension, obesity, physical inactivity, sleep hygiene, and smoking. Participants randomized to the intervention group 2 will undergo counseling by the nurse and guided through the structured, goal-directed AF program. Each participant will receive an AliveCor cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
arm group label: Intervention group 2
intervention type: Other
intervention name: Standard of care
description: Guideline-directed medical therapy according to clinical standard practice at Boston Medical Center.
arm group label: Standard of care group 1
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Robert Helm, MD
role: Principal Investigator
affiliation: Boston Medical Center
facility: 
country: United States
responsible party type: Sponsor
mesh term: Atrial Fibrillation
sharing ipd: No